New LaunchJul 29, 2026, 06:11 AM
Fresenius Medical Care launches BEACON-US for high-volume hemodiafiltration
AI Summary
Fresenius Medical Care announced BEACON-US, a comprehensive scientific research initiative to expand clinical and real-world evidence for high-volume hemodiafiltration (HVHDF) in U.S. dialysis patients. The company is expanding access to HVHDF across the U.S., building on two decades of international evidence supporting improved survival and reduced hospitalization. Early U.S. observations show strong clinical performance, including 40% fewer muscle cramps and improved dialysis adequacy, aligning with landmark studies like CONVINCE. CEO Helen Giza emphasized HVHDF's potential to transform kidney care and its role in the FME Reignite strategy.
Key Highlights
- Fresenius Medical Care launches BEACON-US initiative for high-volume hemodiafiltration (HVHDF) in the U.S.
- Expanding access to HVHDF across the U.S. based on two decades of international evidence.
- Early U.S. data shows 40% fewer muscle cramps with HVHDF therapy.
- Over 70% of treatments using AutoSub plus technology achieve HVHDF target of 23 liters convective volume.
- CONVINCE trial reported 23% lower risk of death for HVHDF patients vs. conventional hemodialysis.
- HVHDF associated with fewer hospitalizations and improved survival in international studies.
- Therapy improves dialysis adequacy (Kt/V) and enables higher convective volumes without extending treatment times.
- U.S. HVHDF treatments utilize Fresenius Medical Care’s 5008X CAREsystem.
Price Impact
More from FMS